145 related articles for article (PubMed ID: 30234387)
1. Efficacy and safety of rituximab plus bendamustine for gastric marginal zone lymphoma.
Cencini E; Fabbri A; Schiattone L; Bocchia M
Leuk Lymphoma; 2019 Mar; 60(3):833-835. PubMed ID: 30234387
[No Abstract] [Full Text] [Related]
2. Endobronchial mucosa-associated lymphoid tissue (MALT) lymphoma.
Yamasaki M; Funaishi K; Muta T; Matsumoto N; Taniwaki M; Hattori N
QJM; 2019 Oct; 112(10):807-808. PubMed ID: 30895318
[No Abstract] [Full Text] [Related]
3. Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study.
Iannitto E; Bellei M; Amorim S; Ferreri AJM; Marcheselli L; Cesaretti M; Haioun C; Mancuso S; Bouabdallah K; Gressin R; Tripodo C; Traverse-Glehen A; Baseggio L; Zupo S; Stelitano C; Castagnari B; Patti C; Alvarez I; Liberati AM; Merli M; Gini G; Cabras MG; Dupuis J; Tessoulin B; Perrot A; Re F; Palombi F; Gulino A; Zucca E; Federico M; Thieblemont C
Br J Haematol; 2018 Dec; 183(5):755-765. PubMed ID: 30407629
[TBL] [Abstract][Full Text] [Related]
4. Long-term efficacy and toxicity of rituximab plus fludarabine and mitoxantrone (R-FM) for gastric marginal zone lymphoma: a single-center experience and literature review.
Cencini E; Fabbri A; Lauria F; Bocchia M
Ann Hematol; 2018 May; 97(5):821-829. PubMed ID: 29340761
[TBL] [Abstract][Full Text] [Related]
5. Hyperhemolysis associated with marginal zone lymphoma.
Yan M; Callum J; Lin Y
Leuk Lymphoma; 2015 Mar; 56(3):829-31. PubMed ID: 24991717
[No Abstract] [Full Text] [Related]
6. Rituximab-Bendamustine (R-Benda) in MALT lymphoma complicating primary Sjögren syndrome (pSS).
Demaria L; Henry J; Seror R; Frenzel L; Hermine O; Mariette X; Nocturne G
Br J Haematol; 2019 Feb; 184(3):472-475. PubMed ID: 29424433
[No Abstract] [Full Text] [Related]
7. Pneumocystis jirovecii pneumonia as a complication of bendamustine in a patient receiving bendamustine plus rituximab for marginal zone lymphoma.
Carter SJ; Bernstein SH; Friedberg JW; Barr PM
Leuk Res; 2011 Nov; 35(11):e223-4. PubMed ID: 21824654
[No Abstract] [Full Text] [Related]
8. Bendamustine-rituximab regimen in untreated indolent marginal zone lymphoma: experience on 65 patients.
Morigi A; Argnani L; Lolli G; Broccoli A; Pellegrini C; Nanni L; Stefoni V; Coppola PE; Carella M; Casadei B; Sabattini E; Cavo M; Zinzani PL
Hematol Oncol; 2020 Oct; 38(4):487-492. PubMed ID: 32594531
[TBL] [Abstract][Full Text] [Related]
9. Treatment of refractory MALT lymphoma by lenalidomide plus bendamustine: A case report.
Zhou Z; Wu P; Wang F; Tao H; Chen Y; Gao J; Chen D; Jia Y
Medicine (Baltimore); 2022 Mar; 101(9):e28938. PubMed ID: 35244050
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal cryoglobulinemia: the first manifestation of gastric marginal B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma).
Gimeno E; Sorlí L; Serrano S; Besses C; Salar A
Leuk Res; 2006 Nov; 30(11):1465-6. PubMed ID: 16481038
[No Abstract] [Full Text] [Related]
11. Minimal change disease: an unusual presentation of marginal zone MALT lymphoma.
Inayat F; Law JK; Myers-Gurevitch PM; Seshan SV; Perlman AS
Clin Nephrol; 2016 Mar; 85(3):184-8. PubMed ID: 26636329
[TBL] [Abstract][Full Text] [Related]
12. Splenic marginal zone lymphoma with a de novo t(8;14)(q24;q32) and a prolymphocytoid evolution responsive to rituximab-bendamustine.
Scapinello G; Pizzi M; Vio S; Nabergoj M; Visentin A; Martines A; Bonaldi L; Trentin L; Semenzato G; Piazza F
Ann Hematol; 2018 Oct; 97(10):2001-2003. PubMed ID: 29728736
[No Abstract] [Full Text] [Related]
13. First-line treatment with bendamustine and rituximab, in patients with intermediate-/high-risk splenic marginal zone lymphomas.
Castelli R; Bergamaschini L; Deliliers GL
Med Oncol; 2017 Dec; 35(2):15. PubMed ID: 29288421
[TBL] [Abstract][Full Text] [Related]
14. Gastric marginal zone lymphoma of mucosa-associated lymphoid tissue type: ESMO clinical recommendations for diagnosis, treatment and follow-up.
; Zucca E
Ann Oncol; 2007 Apr; 18 Suppl 2():ii59-60. PubMed ID: 17491050
[No Abstract] [Full Text] [Related]
15. Rituximab Monotherapy or in Combination with Bendamustine Is Not Inferior to Rituximab-CHOP Regimen in the Treatment of Patients with Splenic Marginal Zone Lymphoma in the Real Life.
Mulas O; Caocci G; Dessì D; Mantovani D; Moi G; Cabras MG; La Nasa G
Acta Haematol; 2021; 144(3):322-326. PubMed ID: 32892194
[TBL] [Abstract][Full Text] [Related]
16. Idelalisib and Rituximab in 17p Deletion-Positive Splenic Marginal Zone Lymphoma.
Philip AZ
J Natl Compr Canc Netw; 2018 Mar; 16(3):230-233. PubMed ID: 29523661
[TBL] [Abstract][Full Text] [Related]
17. IgGκ light and heavy chain amyloidosis secondary to a B-cell lymphoproliferative disorder, whole picture on a renal biopsy.
Ville S; Kandel C; Delaunay J; Cantarovich D
Nephrology (Carlton); 2020 May; 25(5):429-430. PubMed ID: 31726478
[No Abstract] [Full Text] [Related]
18. CD5 expression in marginal zone lymphoma predicts differential response to rituximab or bendamustine/rituximab.
Hsu A; Kurt H; Zayac AS; Olszewski AJ
Leuk Lymphoma; 2022 Jan; 63(1):31-42. PubMed ID: 34467833
[TBL] [Abstract][Full Text] [Related]
19. Treatment of gastric marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue with rituximab, cyclophosphamide, vincristine and prednisone.
Aguiar-Bujanda D; Llorca-Mártinez I; Rivero-Vera JC; Blanco-Sánchez MJ; Jiménez-Gallego P; Mori-De Santiago M; Limeres-Gonzalez MA; Cabrera-Marrero JC; Hernández-Sosa M; Galván-Ruíz S; Hernández-Sarmiento S; Saura Grau S; Bohn-Sarmiento U
Hematol Oncol; 2014 Sep; 32(3):139-44. PubMed ID: 24123108
[TBL] [Abstract][Full Text] [Related]
20. Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a multicenter retrospective analysis.
Hong JY; Yoon DH; Suh C; Kim WS; Kim SJ; Jo JC; Kim JS; Lee WS; Oh SY; Park Y; Kim SY; Lee MH; Lee HS; Do YR
Ann Hematol; 2018 Aug; 97(8):1437-1443. PubMed ID: 29619501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
